Reported 5,972 shares, down 119,231 (95.2%) from the prior quarter.
Reported value -93.2%; share count -95.2% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-09-30 | 56000 |
| 2021-12-31 | 991000 |
| 2022-03-31 | 600000 |
| 2022-06-30 | 643000 |
| 2022-09-30 | 133000 |
| 2022-12-31 | 49949 |
| 2023-03-31 | 227869 |
| 2023-06-30 | 15527 |
| 2023-09-30 | 2840 |
| 2023-12-31 | 3040 |
| 2024-03-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q1 2024 | Reduced | 0 | -1,000 (-100.0%) | 0 | $0 | 2024-05-15 | |
| Q4 2023 | Unchanged | 1,000 | 0 (0.0%) | < 0.01% | $3,040 | 2024-02-13 | |
| Q3 2023 | Reduced | 1,000 | -4,972 (-83.3%) | < 0.01% | $2,840 | 2023-11-15 | |
| Q2 2023 | Reduced | 5,972 | -119,231 (-95.2%) | < 0.01% | $15,527 | 2023-08-14 | |
| Q1 2023 | Added | 125,203 | +94,931 (313.6%) | < 0.01% | $227,869 | 2023-05-15 | |
| Q4 2022 | Reduced | 30,272 | -39,062 (-56.3%) | < 0.01% | $49,949 | 2023-02-14 | |
| Q3 2022 | Reduced | 69,334 | -145,586 (-67.7%) | < 0.01% | $133,000 | 2022-11-14 | |
| Q2 2022 | Added | 214,920 | +55,570 (34.9%) | < 0.01% | $643,000 | 2022-08-15 | |
| Q1 2022 | Added | 159,350 | +72,230 (82.9%) | < 0.01% | $600,000 | 2022-05-13 | |
| Q4 2021 | Added | 87,120 | +83,931 (2631.9%) | < 0.01% | $991,000 | 2022-02-14 | |
| Q3 2021 | New | 3,189 | +3,189 (0.0%) | < 0.01% | $56,000 | 2021-11-15 |
Who else reported the position
45 managers reported CYTEIR THERAPEUTICS INC for Q2 2023.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Novo Holdings A S | Reduced | 3,662,636 | -277,777 | 0.74% | $9,522,854 | 9 qtrs |
| BML Capital Management LLC | Added | 3,250,000 | +103,704 | 7.6% | $8,450,000 | 2 qtrs |
| OUP Management Co LLC | Unchanged | 2,459,572 | 0 | 10.91% | $6,394,887 | 7 qtrs |
| Newtyn Management LLC | Added | 1,358,049 | +405,102 | 0.83% | $3,530,927 | 5 qtrs |
| Anson Funds Management LP | New | 1,151,662 | +1,151,662 | 0.5% | $2,994,321 | 1 qtr |
| FMR LLC | Reduced | 827,867 | -1,424,464 | < 0.01% | $2,152,454 | 9 qtrs |
| VANGUARD GROUP INC | Unchanged | 584,783 | 0 | < 0.01% | $1,520,436 | 9 qtrs |
| Western Standard LLC | New | 524,050 | +524,050 | 1.17% | $1,362,530 | 1 qtr |
| Laurion Capital Management LP | Unchanged | 359,500 | 0 | < 0.01% | $934,700 | 5 qtrs |
| Acuitas Investments LLC | New | 329,173 | +329,173 | 0.5% | $855,850 | 1 qtr |
Filing details and methodology As reported
- Report period
- June 30, 2023
- Filed
- August 14, 2023
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 0
- Shared
- 0
- None
- 5,972
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.